Trial Profile
A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-Uninfected Thai Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP1521 (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- 18 Jul 2010 Results of subject expectations were presented at the 18th International AIDS Conference
- 18 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
- 22 Oct 2009 Results reported in the New England Journal of Medicine.